Arbutus Biopharma (ABUS) Retained Earnings (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Retained Earnings for 17 consecutive years, with -$1.2 billion the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings rose 11.72% year-over-year to -$1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (up 11.72% YoY) and the FY2025 annual result came in at -$1.4 billion, down 2.49% from the prior year.
• Retained Earnings improved to -$1.2 billion in Q1 2026 per ABUS's latest filing, from -$1.4 billion in the prior quarter.
• Over the last five years, Retained Earnings for ABUS reached as high as -$1.2 billion in Q1 2022 and fell as low as -$1.4 billion in Q4 2025.
• A 5-year average of -$1.3 billion and a median of -$1.3 billion in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings retreated 7.94% — and 2026, when it advanced 11.72%.
• Year by year, Retained Earnings stood at -$1.2 billion in 2022, then decreased by 6.05% to -$1.3 billion in 2023, then slipped by 5.48% to -$1.3 billion in 2024, then decreased by 2.49% to -$1.4 billion in 2025, then rose by 12.3% to -$1.2 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$1.2 billion, -$1.4 billion, and -$1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.